Life Science Nation Newsletter  | December 15,  2016  |  Issue 192

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Dec. 8  - Dec. 14)
Invests in Therapeutics, Medical Devices, and Diagnostics in the USA
Invests Early in Oncology and Dermatology
Invests in Infectious Disease, Inflammation and Rare Diseases
Seeks Healthcare IT Focused on Providers
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

LSN Book

LSN Videos
RESI Boston Investors Panel

Calling All Capital Raising CEOs
By Dennis Ford, Founder & CEO, LSN

As crazy as this may sound, LSN has more early stage investors signed up for Redefining Early Stage Investments (RESI) conference (423 registered) than we have fundraising CEOs and scientist-entrepreneurs. I mean think about it! Raising capital is first and foremost a numbers game - you need to get in front of as many investors as possible to increase your chance of meeting the right set of players for your companies stage of development and product. RESI on January 10th at the Marines' Memorial Club & Hotel will provide an unprecedented moment to get you and your firm in front of the two kind of early stage investors that show up at RESI conferences.

The first group typically has a mandate to invest capital in a particular disease, platform or service. This means the money has been appropriated and they are actively seeking firms to fulfill their current investment mandates and allocate funds...

Asian Investors Venturing Boldly for North American Life Science Innovations
By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison

Capital from Asian countries has become a significant force behind life science innovations in North America. On October 10 2016, Zymergen, a Bay Area biotech startup, announced that it closed a massive $130 million Series B round led by the Japanese telecom giant Softbank. The infusion of cash aims to help the three-year-old company build a robot workforce to produce industrial chemicals through genetically altered microbes.

In our previous article, we analyzed US-Asia cross-border investments in life sciences. As we look back on year 2016, the trend seems even clearer. The LSN database recorded 204 pre-IPO equity financing deals in life sciences in North America this year...

By Lucy Parkinson, Director of Research, LSN

RESI has always aimed to represent the diversity of capital sources for early stage life science companies; alongside sessions featuring VCs, pharma, angels, and other traditional sources of capital, LSN is proud to feature two sessions devoted to Family Offices that invest in new healthcare ventures. The Biotech Family Offices sesssion features investors from five different firms who will cover the wide-ranging interests of family offices in the early stage drug development sector.

Moderated by Jayson Rieger, SVP of Business Development & Portfolio Management, PBM Capital, the panelists are:
  • Christine Bunt, Venture Partner, 20/20 HealthCare Partners
  • Will Eden, Vice President, Thiel Capital
  • Daron Evans, Managing Director, PoC Capital
  • Alex Pickett, Associate, Mediqventures